| Company Name: |
Shanghai YuanYe Biotechnology Co., Ltd.
|
| Tel: |
021-61312847; 18021002903 |
| Email: |
3008007409@qq.com |
| Products Intro: |
Product Name:Bersanlimab (anti-ICAM1) CAS:1987854-08-9 Purity:Purity>95% (SDS-PAGE&SEC); Endotoxin Level<1.0EU/mg; Human I Package:100μg Remarks:K13763
|
| Company Name: |
ShangHai Biochempartner Co.,Ltd
|
| Tel: |
177-54423994 17754423994 |
| Email: |
2853530910@QQ.com |
| Products Intro: |
Product Name:Bersanlimab CAS:1987854-08-9 Purity:95% Package:100ug;500ug;1mg
|
| Company Name: |
Guangzhou Hongyuan Chemical Co.,Ltd
|
| Tel: |
15817493340 |
| Email: |
981810490@qq.com |
| Products Intro: |
Product Name:Bersanlimab CAS:1987854-08-9 Purity:95% Package:1mg;1g;100g
|
Bersanlimab manufacturers
- Bersanlimab
-
- $1070.00 / 10mg
-
2026-04-17
- CAS:1987854-08-9
- Min. Order:
- Purity: > 95%
- Supply Ability: 10g
|
| | Bersanlimab Basic information |
| Product Name: | Bersanlimab | | Synonyms: | Bersanlimab;Research Grade Bersanlimab(DHC16001);Research Grade Bersanlimab;BI-505;Bersanlimab (anti-ICAM1) | | CAS: | 1987854-08-9 | | MF: | | | MW: | 0 | | EINECS: | | | Product Categories: | | | Mol File: | Mol File | ![Bersanlimab Structure]() |
| | Bersanlimab Chemical Properties |
| form | Liquid | | color | Colorless to light yellow |
| | Bersanlimab Usage And Synthesis |
| Uses | Bersanlimab (BI-505) is a fully human monoclonal antibody that targets intercellular adhesion molecule-1 (ICAM-1 or CD54). Bersanlimab has anticancer effects[1]. | | in vivo | Bersanlimab (BI-505; 20 mg/kg; i.p.; twice-weekly; for 21 days) significantly reduceds tumor growth and prolonges animal survival[1]. | Animal Model: | SCID mice injected with ARH-77 cells[1] | | Dosage: | 20 mg/kg | | Administration: | i.p.; twice-weekly; for 21 days | | Result: | Significantly reduced tumor growth and prolonged animal survival. |
| | References | [1] Niina Veitonmki, et al. A human ICAM-1 antibody isolated by a function-first approach has potent macrophage-dependent antimyeloma activity in vivo. Cancer Cell. 2013 Apr 15;23(4):502-15. DOI:10.1016/j.ccr.2013.02.026 |
| | Bersanlimab Preparation Products And Raw materials |
|